Moore C - Search Results

1

Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates.

Olivier J, Stavrinides V, Kay J, Freeman A, Pye H, Ahmed Z, Carmona Echeverria L, Heavey S, Simmons LAM, Kanthabalan A, Arya M, Briggs T, Barratt D, Charman SC, Gelister J, Hawkes D, Hu Y, Jameson C, McCartan N, Punwani S, van der Muelen J, Moore C, Emberton M, Ahmed HU, Whitaker HC. Olivier J, et al. Among authors: moore c. Prostate. 2018 Dec;78(16):1229-1237. doi: 10.1002/pros.23698. Epub 2018 Aug 2. Prostate. 2018. PMID: 30073682 Free article.

2

Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer.

Moore CM, Nathan TR, Lees WR, Mosse CA, Freeman A, Emberton M, Bown SG. Moore CM, et al. Lasers Surg Med. 2006 Jun;38(5):356-63. doi: 10.1002/lsm.20275. Lasers Surg Med. 2006. PMID: 16392142 Clinical Trial.

3

Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer.

Ahmed HU, Moore C, Emberton M. Ahmed HU, et al. Among authors: moore c. Surg Oncol. 2009 Sep;18(3):219-32. doi: 10.1016/j.suronc.2009.02.002. Epub 2009 Mar 5. Surg Oncol. 2009. PMID: 19268572 Review.

4

Life after prostate cancer. Time to evaluate focal therapy.

Cathcart P, Ahmed HU, Moore C, Emberton M. Cathcart P, et al. Among authors: moore c. BMJ. 2010 Feb 23;340:c1057. doi: 10.1136/bmj.c1057. BMJ. 2010. PMID: 20179109 No abstract available.

5

Focal therapy in prostate cancer: determinants of success and failure.

Ahmed HU, Moore C, Lecornet E, Emberton M. Ahmed HU, et al. Among authors: moore c. J Endourol. 2010 May;24(5):819-25. doi: 10.1089/end.2009.0665. J Endourol. 2010. PMID: 20380513

6

Photodynamic therapy for focal ablation of the prostate.

Arumainayagam N, Moore CM, Ahmed HU, Emberton M. Arumainayagam N, et al. Among authors: moore cm. World J Urol. 2010 Oct;28(5):571-6. doi: 10.1007/s00345-010-0554-2. Epub 2010 May 9. World J Urol. 2010. PMID: 20454966 Review.

7

The effects of the time period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer.

Dickinson L, Ahmed HU, Moore C, Freeman A, Kirkham A, Allen C, Emberton M. Dickinson L, et al. Among authors: moore c. BJU Int. 2010 Jul;106(1):131-2; author reply 132. doi: 10.1111/j.1464-410X.2010.09451_1.x. BJU Int. 2010. PMID: 20553478 No abstract available.

8

Focal therapy for prostate cancer: fact or fiction?

Lecornet E, Moore C, Ahmed HU, Emberton M. Lecornet E, et al. Among authors: moore c. Urol Oncol. 2010 Sep-Oct;28(5):550-6. doi: 10.1016/j.urolonc.2010.08.004. Urol Oncol. 2010. PMID: 20816615

9

Focal therapy for prostate cancer: a potential strategy to address the problem of overtreatment.

Lecornet E, Ahmed HU, Moore C, Emberton M. Lecornet E, et al. Among authors: moore c. Arch Esp Urol. 2010 Dec;63(10):845-52. Arch Esp Urol. 2010. PMID: 21187566

10

Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.

Simmons L, Ahmed HU, Moore C, Emberton M. Simmons L, et al. Among authors: moore c. BJU Int. 2011 Jan;107(2):338. doi: 10.1111/j.1464-410X.2010.10068_3.x. BJU Int. 2011. PMID: 21208369 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,386 results

Search Page

Filters